Poster Presentations –V th International Eurasian Hematology Congress / Leukemia Research 38 S1 (2014) S1–S65 S33 clinic with complaints of weakness, headaches, widespread body aches and a history of cataract diagnosed at the age of 25 years as well as a cataract operation experienced 5 years ago. TA 110/80 mmHg, 1–2/6 degree systolic murmur and vitilligo marks were present in physical examination. Given an eye exam, the right lense was operated and a capsular cataract was diagnosed in the left eye. The tests resulted with HB 10.37 g/dl, MCV 73.93 fl, Serum iron 16 ug/dl, TDBK 442ug/dl, ferritin >2000 ng/ml, TSH 10.21 uIU/ml, fT4 0.83 ng/dl, anti TPO >600 IU/ml, anti TG 464.3 IU/ml, T.prot, alb, INR, sedim, ANA, CRP, RF, Hb electrophoresis and the Liver MR was normal. Hemachromatosis C282Y and H63 mutations were negative. Unexplained elevated ferritin was present in the 2 daughters of the patient as well as one sibling and a child of the sibling. The ferritin values of the daughters, who were 30 and 27 years old, were found to be 980, 1200 ng/ml respectively and both of them had been diagnosed with cataracts at the age of 12. We also learned that sibling’s daughter was under medical supervision for elevated ferritin and had a phlebotomy at first; however, the phlebotomies were discontinued. Conclusion: HHCS is easily diagnosed with characteristic bilateral early onset cataract and a family history. By diagnosing HHCS, the prognosis shifts to positive. In differential diagnosis with HH, patients should first be genetically examined in terms of HH and invasive procedures such as liver biopsies and phlebotomies should be avoided. PP-018 THE ROLE OF DNMT AND HDACIN THE EXPERIMENTAL HEMORRHAGIC CYSTITIS MODEL IN RATS S. Ozaydin 1 , M. Ozturk 1 , T. Topal 2 , B. Uysal 2 , Y. Gulcan Kurt 3 , B. Kurt 4 , G. Ozgur 5 , F. Arpaci 1 , R. Ogur 6 , A. Korkmaz 2 . 1 GATA Medical Oncology Clinic; 2 GATA Physiology Clinic; 3 GATA Biochemisrty Clinic; 4 GATA Pathology Clinc; 5 GATA Hematology Clinic; 6 GATA PublicHealthClinic Introduction: Cyclophosphamide (CP) is a prodrug and is converted to phosphoramide mustard and acrolein, which is an important reason of hemorragic cystitis (HC). CP induced HC can be seen in 2–40% of pa- tients, which cannot be hindered completely even preventive treatments were used. The pathophysiology of HC is not completely understood. This study focused on the effects of DNA methyltransferase (DNMT) and histondeacetylase (HDAC) activation, which have epigenetic properties. Materials and methods: A total of 50 adult, 12-week-old, 200–250g male Sprague-Dawley rats were randomly distributed into five groups: 1) Sham, 2) Hemorrhagic cystitis (Control), 3) Hemorrhagic cystitis + Valproic acid (VA), 4) Hemorrhagic cystitis 5-Azacytidine (AZ), 5) Hemorrhagic cystitis + Valproic acid + 5-Azacytidine (VA+AZ). Urotoxic dose of 120 mg/kg CP in 2 ml saline was given intraperitoneally. Sham animals were injected with the same amount of saline. VA (300 mg/kg daily intraperitoneally) and AZ (5 mg/kg daily intraperitoneally) were administered 1 hour before CP injection and continued every 12 hours for a total of 6 doses. 72 hours after CP administration, animals were sacrificed and the bladders were removed intact. Bladder MDA, SOD, GSH-Px and TNF-α, IL-1β, IL-10 levels were analyzed. Pathologic examinations were performed. Results: Pathologic parameters and cytokines, oxidant and antioxidant pa- rameters in VA, AZ and AZ+VA groups were superior when compared to the control group as shown in Tables 1 and 2 (P<0.05). Abstract PP-018 – Table 1. Cytokines, oxidant and antioxidant parameters (median ± SD) Groups TNF-α IL-1β IL-10 MDA SOD GSH-Px (pg/g protein) (pg/g protein) (pg/g protein) (mmol/g pro) (U/g pro) (U/g pro) Sham 43.03±12.49 37.48±21.02 166.94±24.86 0.65±0.01 183.95±21.74 45.46±11.09 Control 113.42±55.30 a 86.33±28.11 a 237.62±67.74 a 1.69±0.28 a 65.13±15.22 a 47.35±12.26 VA 51.88±15.66 b 51.91±9.09 b 189.99±24.55 b 0.97±0.18 b 116.32±22.39 b 51.06±9.39 AZ 35.81±11.59 b 35.01±4.62 b 128.61±44.12 b 1.10±0.16 a,b 102.05±15.53 a,b 51.03±11.37 VA+AZ 60.36±15.54 a,b 50.92±17.50 b 152.35±34.96 b 1.01±0.27 a,b 106.99±21.15 a,b 50.09±9.35 a P<0.05 compared with Sham group, b P<0.05 compared with Control group. Abstract PP-018 – Table 2. Pathologic scores and bladder weight/body weight ratio (median (min–max)) Groups Hemorrage Edema Inflammation Necrosis BLW/BW Sham 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.473 (0.320–0.656) Control 2 (1–3) a 3.5 (1–4) a 2 (1–3) a 0 (0–2) 1.196 (0.818–1.583) a VA 0.5 (0–3 b 1 (0–3 b 1 (0–2 b 0 (0–1) 0.784 (0.516–1.172) a,b AZ 1.5 (0–2) a,b 2 (0–3) a,b 1 (0–2) a,b 0 (0–1) 0.861 (0.495–1.182) a,b VA+AZ 1 (0–3) a,b 2 (1–3) a,b 1 (0–2) a,b 0 (0–1) 0.734 (0.505–1.035) a,b a P<0.05 compared with Sham group, b P<0.05 compared with Control group. Conclusion: AZ, VA, AZ+VA is an effective treatment for the experimental hemorrhagic cystitis model in rats. PP-019 OCULAR ADNEXAL LYMPHOMAS: SINGLE CENTER EXPERIENCE M. Comert Ozkan 1 , M. Palamar Onay 2 , M. Tombuloglu 1 , M. Hekimgil 3 , N. Ozsan 3 , G. Saydam 1 , F. Sahin 1 . 1 Department of Hematology, 2 Department of Ophthalmology,; 3 Department of Pathology, Ege University, School of Medicine Context: Ocular adnexal lymphomas (OALs) are rare manifestations of non-Hodgkin lymphomas (NHLs), accounting for 1% to 2% of all NHLs and about 8% of the extranodal lymphomas, however the incidence of OAL has increased by approximately 6% annually in last 20 years. Objective: Determining OALs frequency and optimal treatment in our clinic and evaluating the outcomes. Design: Eighteen OAL cases diagnosed in our pathology department be- tween 2004 and 2014 was evaluated retrospectively in terms of disease localization, type of treatment, and outcomes based on our hospital records. Results: Six (33.3%) of the cases were marginal zone lymphoma (MZL) (3 ENMZ5L, 3 NMZL), 5 (27.8%) mantle cell lymphoma (MCL) (3 blastoid variant), 3 (16.7%) diffuse large B cell lymphoma (DBBHL), 2 (11.1%) follic- ular lymphoma and 1 (5.6%) was lymphoblastic lymphoma. 15 cases were followed in our clinic. Eight (53.3%) cases were primary OAL, 5 (33.3%) were initial sign of systemic lymphoma and 2 (13.3%) cases were diagnosed in the course of lymphoma. 7 primary OAL cases were treated with radiation therapy, systemic lymphomas and one of primary lymphoma, which was bulky disease, were treated with chemotherapy. Two cases (in the course of FL and primary ENMZL) had relapsed diseases. Conclusion: More than half of the cases of OALs are mucosa-associated lymphoid tissue (MALT) lymphomas; mantle cell lymphoma, especially blastoid variant and extranodal marginal zone lymphoma was relatively more frequent in our clinic. Due to high relapse rates, systemic treat- ment can be considered particularly in bulky and/or destructive diseases. Radiotherapy should be a part of therapy in certain cases. PP-020 AN ESSENTIAL THROMBOCYTOSIS CASE, WHICHTRANSFORMED TO ACUTE MYELOID LEUKEMIA AFTER 12 YEARS Ü.Y. Malkan , G. Güne ¸ s, E. Eliaçık, A. I ¸ sık, N. Sayınalp, O. ˙ I. Özcebe, ˙ I.C. Haznedaro˘ glu. Hacettepe University, School of Medicine,Department of Hematology Essential thrombocytosis (ET) is classified in bcr/abl negative myelopro- liferative diseases. Most of essential thrombocytosis cases have normal survival time without complication. Here we described an ET case, which transformed in to acute myeloid leukemia (AML) after 12 years of follow-up. In 2007, a 68-year-old female patient applied to general surgery department with abdominal pain. She was diagnosed as ET in 1995 and she had used hydroxycarbamide (HC). Retrospective investigations revealed her hemoglobin levels were below 12g/dl since 2011 and platelet levels were never above 1,000,000/μl. In May 2007 her platelet has started to fall so blood smear performed and 15% blast observed. Marrow investigation